Study of in vitro and in vivo effects of the piperidine nitroxide Tempol - A potential new therapeutic agent for gliomas

M. B. Gariboldi, R. Ravizza, C. Petterino, M. Castagnaro, G. Finocchiaro, Elena Monti

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The identification of novel therapeutic agents for the management of malignant gliomas represents an area of active research. Here, we show that Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl; TPL), a stable nitroxide free radical, inhibits the growth of C6 glioma cells both in vitro and in vivo. Morphological features of apoptosis were apparent in C6 cells following in vitro treatment with TPL. Cell death was preceded by dose-dependent increase in p21WAF1/CIP1 expression, without apparent stabilisation of the TP53 gene product. When C6 cells were grown as xenografts in nude mice, treatment with TPL induced a significant dose-dependent decrease in tumour growth, without signs of general or organ toxicity. Tumours from treated mice showed an increase in the number of apoptotic cells and a decrease in the rate of neo-vascularisation compared with tumours from control mice. Our findings suggest a potential use for TPL as a novel antiproliferative agent for the treatment of malignant gliomas.

Original languageEnglish
Pages (from-to)829-837
Number of pages9
JournalEuropean Journal of Cancer
Volume39
Issue number6
DOIs
Publication statusPublished - Apr 2003

Fingerprint

Glioma
Neoplasms
p53 Genes
Growth
Heterografts
Nude Mice
Free Radicals
Cell Death
Therapeutics
Cell Count
Apoptosis
Research
piperidine
tempol
In Vitro Techniques
nitroxyl

Keywords

  • Antitumour effects
  • Glioma
  • p21
  • Tempol

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Study of in vitro and in vivo effects of the piperidine nitroxide Tempol - A potential new therapeutic agent for gliomas. / Gariboldi, M. B.; Ravizza, R.; Petterino, C.; Castagnaro, M.; Finocchiaro, G.; Monti, Elena.

In: European Journal of Cancer, Vol. 39, No. 6, 04.2003, p. 829-837.

Research output: Contribution to journalArticle

Gariboldi, M. B. ; Ravizza, R. ; Petterino, C. ; Castagnaro, M. ; Finocchiaro, G. ; Monti, Elena. / Study of in vitro and in vivo effects of the piperidine nitroxide Tempol - A potential new therapeutic agent for gliomas. In: European Journal of Cancer. 2003 ; Vol. 39, No. 6. pp. 829-837.
@article{6680931173d749d7a4411808d85da271,
title = "Study of in vitro and in vivo effects of the piperidine nitroxide Tempol - A potential new therapeutic agent for gliomas",
abstract = "The identification of novel therapeutic agents for the management of malignant gliomas represents an area of active research. Here, we show that Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl; TPL), a stable nitroxide free radical, inhibits the growth of C6 glioma cells both in vitro and in vivo. Morphological features of apoptosis were apparent in C6 cells following in vitro treatment with TPL. Cell death was preceded by dose-dependent increase in p21WAF1/CIP1 expression, without apparent stabilisation of the TP53 gene product. When C6 cells were grown as xenografts in nude mice, treatment with TPL induced a significant dose-dependent decrease in tumour growth, without signs of general or organ toxicity. Tumours from treated mice showed an increase in the number of apoptotic cells and a decrease in the rate of neo-vascularisation compared with tumours from control mice. Our findings suggest a potential use for TPL as a novel antiproliferative agent for the treatment of malignant gliomas.",
keywords = "Antitumour effects, Glioma, p21, Tempol",
author = "Gariboldi, {M. B.} and R. Ravizza and C. Petterino and M. Castagnaro and G. Finocchiaro and Elena Monti",
year = "2003",
month = "4",
doi = "10.1016/S0959-8049(02)00742-6",
language = "English",
volume = "39",
pages = "829--837",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "6",

}

TY - JOUR

T1 - Study of in vitro and in vivo effects of the piperidine nitroxide Tempol - A potential new therapeutic agent for gliomas

AU - Gariboldi, M. B.

AU - Ravizza, R.

AU - Petterino, C.

AU - Castagnaro, M.

AU - Finocchiaro, G.

AU - Monti, Elena

PY - 2003/4

Y1 - 2003/4

N2 - The identification of novel therapeutic agents for the management of malignant gliomas represents an area of active research. Here, we show that Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl; TPL), a stable nitroxide free radical, inhibits the growth of C6 glioma cells both in vitro and in vivo. Morphological features of apoptosis were apparent in C6 cells following in vitro treatment with TPL. Cell death was preceded by dose-dependent increase in p21WAF1/CIP1 expression, without apparent stabilisation of the TP53 gene product. When C6 cells were grown as xenografts in nude mice, treatment with TPL induced a significant dose-dependent decrease in tumour growth, without signs of general or organ toxicity. Tumours from treated mice showed an increase in the number of apoptotic cells and a decrease in the rate of neo-vascularisation compared with tumours from control mice. Our findings suggest a potential use for TPL as a novel antiproliferative agent for the treatment of malignant gliomas.

AB - The identification of novel therapeutic agents for the management of malignant gliomas represents an area of active research. Here, we show that Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl; TPL), a stable nitroxide free radical, inhibits the growth of C6 glioma cells both in vitro and in vivo. Morphological features of apoptosis were apparent in C6 cells following in vitro treatment with TPL. Cell death was preceded by dose-dependent increase in p21WAF1/CIP1 expression, without apparent stabilisation of the TP53 gene product. When C6 cells were grown as xenografts in nude mice, treatment with TPL induced a significant dose-dependent decrease in tumour growth, without signs of general or organ toxicity. Tumours from treated mice showed an increase in the number of apoptotic cells and a decrease in the rate of neo-vascularisation compared with tumours from control mice. Our findings suggest a potential use for TPL as a novel antiproliferative agent for the treatment of malignant gliomas.

KW - Antitumour effects

KW - Glioma

KW - p21

KW - Tempol

UR - http://www.scopus.com/inward/record.url?scp=0037376807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037376807&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(02)00742-6

DO - 10.1016/S0959-8049(02)00742-6

M3 - Article

C2 - 12651210

AN - SCOPUS:0037376807

VL - 39

SP - 829

EP - 837

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 6

ER -